ARPP19 and acute myeloid leukemia: Importantly, supportive of the oncogenic role for ARPP19 in human AML, patients without relapse during the follow-up time had significantly lower ARPP19 expression than patients that relapsed during the follow-up time (Figure 4a, p = 0.035 by Wilcoxon rank-sum test).